According to Zacks, “Cambrex Corporation manufactures and markets a broad line of specialty chemicals and commodity chemical intermediates and also manufactures chemicals to customer specifications. There are five product categories: pharmaceutical bulk actives; pharmaceutical intermediates; organic intermediates; performance enhancers; and polymer systems. “
Cambrex Corp. (NYSE:CBM) opened at 45.22 on Tuesday. The firm has a 50-day moving average price of $45.28 and a 200-day moving average price of $47.69. Cambrex Corp. has a one year low of $29.50 and a one year high of $59.41. The firm has a market cap of $1.45 billion, a PE ratio of 22.86 and a beta of 1.45.
Cambrex Corp. (NYSE:CBM) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.09. Cambrex Corp. had a return on equity of 24.86% and a net margin of 13.97%. The firm earned $118.22 million during the quarter, compared to analyst estimates of $114.85 million. During the same period last year, the company earned $0.63 earnings per share. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities analysts expect that Cambrex Corp. will post $2.56 EPS for the current fiscal year.
In related news, Director William B. Korb sold 3,420 shares of Cambrex Corp. stock in a transaction on Monday, July 11th. The stock was sold at an average price of $55.00, for a total transaction of $188,100.00. Following the completion of the sale, the director now owns 23,982 shares of the company’s stock, valued at $1,319,010. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.63% of the company’s stock.
A number of large investors have recently bought and sold shares of CBM. Mason Street Advisors LLC acquired a new stake in Cambrex Corp. during the second quarter valued at about $323,000. Royal Bank of Canada raised its stake in Cambrex Corp. by 1.2% in the second quarter. Royal Bank of Canada now owns 60,197 shares of the company’s stock valued at $3,114,000 after buying an additional 707 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in Cambrex Corp. by 7.8% in the second quarter. Public Employees Retirement System of Ohio now owns 92,159 shares of the company’s stock valued at $4,767,000 after buying an additional 6,668 shares in the last quarter. Stifel Financial Corp raised its stake in Cambrex Corp. by 5.0% in the second quarter. Stifel Financial Corp now owns 11,363 shares of the company’s stock valued at $588,000 after buying an additional 543 shares in the last quarter. Finally, Fiera Capital Corp acquired a new stake in Cambrex Corp. during the second quarter valued at about $23,842,000. 99.46% of the stock is owned by institutional investors.
Cambrex Corp. Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.